Zhang Linsheng, Deeb George, Deeb Kristin K, Vale Colin, Peker Barclift Deniz, Papadantonakis Nikolaos
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
Cancers (Basel). 2024 Apr 15;16(8):1503. doi: 10.3390/cancers16081503.
Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, and molecular and flow cytometry techniques have been used in several studies. In this review, we will highlight the evolving concept of MRD in MDS, outline the various techniques utilized, and provide an overview of the studies reporting MRD and the correlation with outcomes.
骨髓增生异常综合征（MDS）传统上是通过血细胞计数、细胞遗传学和形态学评估来进行研究的。近年来，分子检测方法的引入提高了我们诊断MDS的能力。可测量（微小）残留病（MRD）在MDS中的作用正在不断演变，分子技术和流式细胞术已在多项研究中得到应用。在本综述中，我们将重点介绍MDS中MRD这一不断演变的概念，概述所采用的各种技术，并对报告MRD及其与预后相关性的研究进行综述。
Zotero 插件